Infectious complications in adult acute myeloid leukemia: Analysis of the Acute Leukemia French Association-9802 prospective multicenter clinical trial

Leukemia and Lymphoma

Volumn 53, Issue 6, 2012, Pages 1068-1076

  Cannas, Giovanna ^a   Pautas, Cécile ^b   Raffoux, Emmanuel ^c   Quesnel, Bruno ^d   Botton, Stéphane De ^e   Revel, Thierry De ^f   Reman, Oumedaly ^g   Gardin, Claude ^h   Elhamri, Mohamed ^a   Boissel, Nicolas ^c   Fenaux, Pierre ^h   Michallet, Mauricette ^a   Castaigne, Sylvie ⁱ   Dombret, Hervé ^c   Thomas, Xavier ^a  

^a EDOUARD HERRIOT HOSPITAL   (France)

^b HENRI MONDOR HOSPITAL   (France)

^c SAINT LOUIS HOSPITAL   (France)

^d LILLE UNIVERSITY HOSPITAL   (France)

^e INSTITUT GUSTAVE ROUSSY   (France)

^f PERCY MILITARY HOSPITAL   (France)

^g Centre de Gerontologie Georges CLEMENCEAU   (France)

^h AVICENNE HOSPITAL   (France)

ⁱ CENTRE HOSPITALIER DE VERSAILLES   (France)

Author keywords

Acute myeloid leukemia; Aspergillosis; Chemotherapy; Infection; Prognosis

Indexed keywords

ANTINEOPLASTIC AGENT;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; BLOODSTREAM INFECTION; CANCER CHEMOTHERAPY; CAUSE OF DEATH; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; FEMALE; FEVER; GRAM NEGATIVE INFECTION; GRAM POSITIVE INFECTION; HOSPITALIZATION; HUMAN; INCIDENCE; LUNG INFECTION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MEDICAL SOCIETY; MORBIDITY; MORTALITY; MULTICENTER STUDY; MYCOSIS; OVERALL SURVIVAL; PATIENT CARE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SALVAGE THERAPY; TREATMENT RESPONSE;

ADOLESCENT; ADULT; CONSOLIDATION CHEMOTHERAPY; FEMALE; FRANCE; HUMANS; INDUCTION CHEMOTHERAPY; INFECTION; LEUKEMIA, MYELOID, ACUTE; MALE; MEDICAL ONCOLOGY; MIDDLE AGED; PROSPECTIVE STUDIES; SALVAGE THERAPY; SOCIETIES, MEDICAL; YOUNG ADULT;

EID: 84861372982     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2011.636812     Document Type: Article

References (40)

1. Th omas X, Raff oux E, Botton S, et al. Effect of priming with granulocyte-macrophage colony-stimulating factor in younger adults with newly diagnosed acute myeloid leukemia: a trial by the Acute Leukemia French Association (ALFA) Group. Leukemia 2007;21: 453-461.
2. Feusner JH, Hastings CA. Infections in children with acute myelogenous leukemia. Concepts of management and prevention. J Pediatr Hematol Oncol 1995;17:234-247.
3. Cordonnier C, Buzyn A, Leverger G, et al.; Club de Ré fl exion sur les Infections en Onco-H é matologie. Epidemiology and risk factors for Gram-positive coccal infections in neutropenia: toward a more targeted antibiotic strategy. Clin Infect Dis 2003;36:149-158. (Pubitemid 36143411)
4. Tobias JS, Wrigley PF, O ' Grady F. Bacterial infection and acute myeloblastic leukaemia: an analysis of two hundred patients undergoing intensive remission induction therapy. Eur J Cancer 1978;14:383-391. (Pubitemid 8310449)
5. Madani TA. Clinical infections and bloodstream isolates associated with fever in patients undergoing chemotherapy for acute myeloid leukemia. Infection 2000;28:367-373.
6. Bennett JM, Catovsky D, Daniel MT, et al. Proposed revised criteria for the classifi cation of acute myeloid leukemia:a report of the French- American-British Cooperative Group. Ann Intern Med 1985;103: 626-629.
7. Castaigne C, Chevret S, Archimbaud E, et al. Randomized comparison of double induction and timed-sequentialinduction to a " 3 + 7 " induction in adults with AML: long-term analysis of the Acute Leukemia French Association (ALFA) 9000 study. Blood 2004;104:2467-2474. (Pubitemid 39331849)
8. Mayer RJ, Davies RB, Schiff er CA, et al. Intensive post-remission chemotherapy in adults with acute myeloid leukemia: Cancer and Leukemia Group B. N Engl J Med 1994;331:896-903. (Pubitemid 24299870)
9. Cheson BD, Cassileth PA, Head DR, et al. International working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol 2003;21:4642-4649. (Pubitemid 46594039)
10. Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 2011;52:56-93.
11. Wisplinghoff H, Seifert H, Wenzel RP, et al. Current trends in the epidemiology of nosocomial bloodstream infections in patients with hematological malignancies and solid neoplasms in hospitals in the United States. Clin Infect Dis 2003;36:1103-1110. (Pubitemid 36553108)
12. Ascioglu S, Rex JH, de Pauw B, et al. Defi ning opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002;34:7-14. (Pubitemid 33152659)
13. Th omas X, Raff oux E, Renneville A, et al. Which AML subsets benefi t from leukemic cell priming during chemotherapy? Long-term analysis of the ALFA-9802 GM-CSF study. Cancer 2010;116:1725-1732.
14. World Health Organization. World Health Organization handbook for reporting results of cancer treatment. WHO Off set Publication No. 48. Geneva: WHO; 1979. pp 1-45.
15. Crawford J, Dale DC, Lyman GH. Chemotherapy-induced neutropenia: risks, consequences, and new direction for its management. Cancer 2004;100:228-237. (Pubitemid 38063629)
16. Malagola M, Peli A, Damiani D, et al. Incidence of bacterial and fungal infections in newly diagnosed acute myeloid leukaemia patients younger than 65 years treated with induction regimens including fl udarabine: retrospective analysis of 224 cases. Eur J Haematol 2008;81:354-363.
17. Pagano L, Caira M, Candoni A, et al. The epidemiology of fungal infections in patients with hematologic malignancies: the SEI-FEM- 2004 study. Haematologica 2006;91:1068-1075. (Pubitemid 44208634)
18. Klastersky J, Zinner SH, Calandra T, et al. Empiric antimicrobial therapy for febrile granulocytopenic cancer patients: lessons from four EORTC trials. Eur J Cancer Clin Oncol 1988;24:S35-S45. (Pubitemid 18051215)
19. Klastersky J, Ameye L, Maertens J, et al. Bacteraemia in febrile neutropenic cancer patients. Int J Antimicrob Agents 2007;30 (Suppl. 1):S51-S59.
20. Cruciani M, Rampazzo R, Malena M, et al. Prophylaxis with fl uoroquinolones for bacterial infections in neutropenic patients:a meta-analysis. Clin Infect Dis 1996;23:795-805. (Pubitemid 26331127)
21. Rubio M, Palau L, Vivas JR, et al. Predominance of gram-positive microorganisms as a cause of septicemia in patients with hematological malignancies. Infect Control Hosp Epidemiol 1994;15:101-104.
22. Rabbat A, Chaoui D, Lefebvre A, et al. Is BAL useful in patients with acute myeloid leukemia admitted in ICU for severe respiratory complications? Leukemia 2008;22:1361-1367. (Pubitemid 352011840)
23. De Pauw B, Walsh TJ, Donnelly JP, et al. Revised defi nitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008;46:1813-1821.
24. Gerson SL, Talbot GH, Hurwitz S, et al. Prolonged granolucytopenia: the major risk factor for invasive aspergillosis in patients with acute leukaemia. Ann Intern Med 1984;100:345-357.
25. Van Gool R. The cost of treating systemic fungal infections. Drugs 2001;61(Suppl. 1):49-56. (Pubitemid 32151112)
26. Martino R, Lopez R, Sureda A, et al. Risk of reactivation of a recent invasive fungal infection in patients with hematological malignancies undergoing further intensive chemotherapy: a single center experience and review of the literature. Haematologica 1997;82:297-304. (Pubitemid 28023304)
27. Kullberg BJ, Sobel JD, Ruhnke M, et al. Voriconazole versus a regimen of amphotericin B followed by fl uconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial. Lancet 2005;366:1435-1442. (Pubitemid 41483809)
28. Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002;347:408-415. (Pubitemid 34851833)
29. Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008;46:327-360. (Pubitemid 351265310)
30. Cordonnier C, Rovira M, Maertens J, et al. Voriconazole for secondary prophylaxis of invasive fungal infections in allogeneic stem cell transplant recipients: results of the VOSIFI study. Haematologica 2010;95:1762-1768.
31. Sonis ST. Oral complications of cancer therapy. In: Devita VT, Hellman S, Rosenberg SA, editors. Cancer, principles and practice of oncology. 2nd ed. Philadelphia: JB Lippincott; 1985. pp 2014-2021.
32. Aksoy DY, Tanriover MD, Uzun O, et al. Diarrhea in neutropenic patients: a prospective cohort study with emphasis on neutropenic enterocolitis. Ann Oncol 2007;18:183-189. (Pubitemid 46152520)
33. Gorschlü t er M, Mey U, Strehl J, et al. Invasive fungal infections in neutropenic enterocolitis: a systematic analysis of pathogens, incidence, treatment and mortality in adult patients. BMC Infect Dis 2006;6:35.
34. Wolfson JS, Sober AJ. Dermatologic manifestations of infection in the compromised host. In: Rubin RH, Young LS, editors. Clinical approach of infection in the compromised host. 2nd ed. New York: Plenum Medical; 1986. pp 115-130.
35. Riley LC, Hann IM, Wheatley K, et al. Treatment-related deaths during induction and fi rst remission of acute myeloid leukaemia in children treated on the Tenth Medical Research Council acute myeloid leukaemia trial (MRC AML 10). Br J Haematol 1999;106:436-444. (Pubitemid 29450670)
36. Lehrnbecher T, Varwig D, Kaiser J, et al. Infectious complications in pediatric acute myeloid leukemia: analysis of the prospective multiinstitutional clinical trial AML-BFM 93. Leukemia 2004;18:72-77. (Pubitemid 38159441)
37. Robenshtok E, Gafter-Gvili A, Goldberg E, et al. Antifungal prophylaxis in cancer patients after chemotherapy or hematopoietic stem cell transplantation: systematic review and meta-analysis. J Clin Oncol 2007;25:5471-5489. (Pubitemid 350232225)
38. Cornely OA, Maertens J, Winston DJ, et al. Posaconazole vs. fl uconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007;356:348-359. (Pubitemid 46148777)
39. Bucaneve G, Micozzi A, Menichetti F, et al. Levofl oxacin to prevent bacterial infection in patients with cancer and neutropenia. N Engl J Med 2005;353:977-987. (Pubitemid 41262332)
40. Pagano L, Caira M, Nosari A, et al. Fungal infections in recipients of hematopoietic stem cell transplants: results of the SEIFEM B-2004 study-Sorveglianza Epidemiologica Infezioni Fungine Nelle Emopatie Maligne. Clin Infect Dis 2007;45:1161-1170. (Pubitemid 47580314)